Drug Profile
Research programme: Mnk inhibitor - Swedish Orphan Biovitrum
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Biovitrum
- Developer Swedish Orphan Biovitrum
- Class
- Mechanism of Action MKNK1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Type 2 diabetes mellitus
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Sweden
- 14 Jan 2010 Biovitrum has merged with Swedish Orphan to form Swedish Orphan Biovitrum
- 07 Feb 2008 The programme is available for licensing (http://www.biovitrum.com)